Data

Remdesivir Coronavirus Trial: Federal Scientists Finally Publish Data

Nearly a month after federal scientists claimed that an experimental drug had helped patients severely ill with the coronavirus, the research has been published.

The drug, remdesivir, was quickly authorized by the Food and Drug Administration for treatment of coronavirus patients, and hospitals rushed to obtain supplies.

But until now, researchers and physicians had not seen the actual data. And remdesivir, made by Gilead Sciences, has a spotty history. It was originally intended to treat hepatitis, but it failed to. It was tested against Ebola, but results were lackluster.

So far, remdesivir has not been officially approved for any purpose. The F.D.A.’s emergency use authorization was not a formal approval.

The long-awaited study, sponsored by the National Institute of Allergy and Infectious Diseases, appeared on The New England Journal of Medicine website on Friday evening. It confirms the essence of the government’s assertions: Remdesivir shortened recovery time from 15 days

Read More

F.D.A. Orders Companies to Submit Antibody Test Data

The Food and Drug Administration announced on Monday that companies selling coronavirus antibody tests must submit data proving accuracy within the next 10 days or face removal from the market.

The antibody tests are an effort to detect whether a person had been infected with the coronavirus, but results have been widely varied. Since mid-March, the agency has permitted dozens of manufacturers to sell the tests without providing evidence that they are accurate.

The agency has also been under fire from several members of Congress, with numerous lawmakers raising

Read More

Arthritis Drug Did Not Help Seriously Ill Covid Patients, Early Data Shows

Doctors around the world, trying to save seriously ill coronavirus patients, have been dosing them with rheumatoid arthritis drugs that can squelch immune responses. The theory was that many were dying because their immune systems went into overdrive, creating a fatal storm that attacked their lungs.

But now, preliminary results on treatments with one of these drugs, sarilumab, marketed as Kevzara and made by Regeneron and Sanofi, indicate that it does not help patients who are hospitalized but not using ventilators.

The rush to treat patients with rheumatoid arthritis drugs began with a tiny study in China in February. It involved just 21 patients, all of whom were hospitalized with Covid-19. All of the patients received a drug made by Roche, tocilizumab, that is very similar to sarilumab. The doctors reported that the patients’ fevers disappeared within days and, the doctors wrote, that “all other symptoms improved remarkably.” They ended

Read More

Asthma Is Absent Among Top Covid-19 Risk Factors, Early Data Shows

Dr. Linda Rogers, a specialist in pulmonary medicine at the Mt. Sinai Health system, which is on the front line of Covid treatment, said one would assume that patients with underlying lung diseases would be “at risk of worse outcomes.” But she said that “asthma is underrepresented” in patients that are sick enough to seek treatment.

Her practice focuses on people with more serious cases of asthma, but she has been able to successfully manage many of her asthma patients through telemedicine. “These are patients who, just based on their asthma alone, are on steroids all the time. I’m just surprised some of them haven’t done worse.”

Still, the data analysis on the effects of asthma is in its infancy, and health experts cited an existing body of research that shows the flu and milder coronaviruses exacerbate asthma as worrisome indicators for those with Covid-19. Dr. Rogers said that she

Read More